The Implementation of Anti-Amyloid Therapeutics for Alzheimer’s
Disease—Practical Considerations for Pharmacists Regarding Preparation, Access to Care, and Counseling
Pre-test

Questions marked with a * are required
100%
Contact Information
Which statement best describes the efficacy outcomes seen with lecanemab in the CLARITY-AD trial?
Which statement best describes the efficacy outcomes seen with lecanemab in the CLARITY-AD trial?
When counseling a patient/care partner about starting an anti-amyloid therapy, which monitoring parameter is most critical to discuss?
When counseling a patient/care partner about starting an anti-amyloid therapy, which monitoring parameter is most critical to discuss?
Which protocol is correct for donanemab?
Which protocol is correct for donanemab?
Which statement about Medicare coverage of anti-amyloid therapies is correct?
Which statement about Medicare coverage of anti-amyloid therapies is correct?
During administration of lecanemab, a 72-year-old patient develops chills, fever and mild nausea 20 minutes into her first infusion. Her blood pressure is 138/82 mmHg and oxygen saturation is 97%. As the infusion pharmacist, what is the most appropriate next step?
During administration of lecanemab, a 72-year-old patient develops chills, fever and mild nausea 20 minutes into her first infusion. Her blood pressure is 138/82 mmHg and oxygen saturation is 97%. As the infusion pharmacist, what is the most appropriate next step?
Mrs. Rodriguez is 72 with mild cognitive impairment (MCI) due to Alzheimer's disease (confirmed by positive amyloid PET scan). She is being evaluated for anti-amyloid therapy. Brain MRI shows no evidence of cerebral or micro hemorrhages. She takes apixaban 5 mg twice daily for atrial fibrillation. Based on current clinical evidence regarding anti-amyloid therapeutics, which of the following is the most appropriate recommendation? 
Mrs. Rodriguez is 72 with mild cognitive impairment (MCI) due to Alzheimer's disease (confirmed by positive amyloid PET scan). She is being evaluated for anti-amyloid therapy. Brain MRI shows no evidence of cerebral or micro hemorrhages. She takes apixaban 5 mg twice daily for atrial fibrillation. Based on current clinical evidence regarding anti-amyloid therapeutics, which of the following is the most appropriate recommendation? 
Powered by QuestionPro